Glioblastoma and other primary brain malignancies in adults: a review
Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
United States. The annual incidence of primary malignant brain tumors is approximately 7 …
Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches
K Mitusova, OO Peltek, TE Karpov… - Journal of …, 2022 - Springer
Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …
therapy, currently, there is no significant progress in the treatment of different types of brain …
Primary CNS lymphoma
C Grommes, LM DeAngelis - Journal of Clinical Oncology, 2017 - ascopubs.org
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is
typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic …
typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic …
Primary central nervous system lymphoma
LR Schaff, C Grommes - Blood, The Journal of the American …, 2022 - ashpublications.org
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous
malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without …
malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without …
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first …
AJM Ferreri, K Cwynarski, E Pulczynski… - The Lancet …, 2016 - thelancet.com
Background Standard treatment for patients with primary CNS lymphoma remains to be
defined. Active therapies are often associated with increased risk of haematological or …
defined. Active therapies are often associated with increased risk of haematological or …
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients …
AJM Ferreri, K Cwynarski, E Pulczynski… - The Lancet …, 2017 - thelancet.com
Summary Background The International Extranodal Lymphoma Study Group-32 (IELSG32)
trial is an international randomised phase 2 study that addresses two key clinical questions …
trial is an international randomised phase 2 study that addresses two key clinical questions …
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack… - Annals of …, 2015 - annalsofoncology.org
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
K Hoang-Xuan, E Bessell, J Bromberg… - The Lancet …, 2015 - thelancet.com
The management of primary CNS lymphoma is one of the most controversial topics in neuro-
oncology because of the complexity of the disease and the very few controlled studies …
oncology because of the complexity of the disease and the very few controlled studies …
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
K Hoang-Xuan, M Deckert, AJM Ferreri… - Neuro …, 2023 - academic.oup.com
The management of primary central nervous system (PCNSL) is one of the most
controversial topics in neuro-oncology because of the complexity of the disease and the …
controversial topics in neuro-oncology because of the complexity of the disease and the …
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
JEC Bromberg, S Issa, K Bakunina… - The Lancet …, 2019 - thelancet.com
Background The prognosis for primary CNS lymphoma has improved with the use of high-
dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a …
dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a …